Childhood T-cell acute lymphoblastic leukemia (T-ALL) still remains a therapeutic challenge due to relapses which are resistant to further treatment. L-asparaginase (ASNase) is a key therapy component in pediatric T-ALL and lower sensitivity of leukemia cells to this drug negatively influences overall treatment efficacy and outcome. PTEN protein deletion and/or activation of the PI3K/Akt signaling pathway leading to altered cell growth and metabolism are emerging as a common feature in T-ALL. We herein investigated the relationship amongst PTEN deletion, ASNase sensitivity and glucose metabolism in T-ALL cells. First, we found significant differences in the sensitivity to ASNase amongst T-ALL cell lines. While cell lines more sensitive to ASNase were PTEN wild type (WT) and had no detectable level of phosphorylated Akt (P-Akt), cell lines less sensitive to ASNase were PTEN-null with high P-Akt levels. Pharmacological inhibition of Akt in the PTEN-null cells rendered them more sensitive to ASNase and lowered their glycolytic function which then resembled PTEN WT cells. In primary T-ALL cells, although P-Akt level was not dependent exclusively on PTEN expression, their sensitivity to ASNase could also be increased by pharmacological inhibition of Akt. In summary, we highlight a promising therapeutic option for T-ALL patients with aberrant PTEN/PI3K/Akt signaling.

CLIP Prague Czech Republic

Department of Pediatric Hematology and Oncology 2nd Faculty of Medicine Charles University Prague Czech Republic

University Hospital Motol Prague Czech Republic

Zobrazit více v PubMed

Karrman K, Johansson B. Pediatric T-cell acute lymphoblastic leukemia. Genes Chromosom. Cancer. 2017;56:89–116. PubMed

Schrappe M, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118:2077–2084. PubMed

Van Vlierberghe P, Pieters R, Beverloo HB, Meijerink JPP. Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br. J. Haematol. 2008;143:153–168. PubMed

Nguyen K, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: A Children’s Oncology Group study. Leukemia. 2008;22:2142–2150. PubMed PMC

Einsiedel HG, et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: Results of trial Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Münster Group 87. J. Clin. Oncol. 2005;23:7942–7950. PubMed

Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematology. 2016;2016:580–588. PubMed PMC

Chen SH. Asparaginase therapy in pediatric acute lymphoblastic leukemia: A focus on the mode of drug resistance. Pediatr. Neonatol. 2015;56:287–293. PubMed

Pession A, et al. Long-term results of a randomized trial on extended use of high dose l-asparaginase for standard risk childhood acute lymphoblastic leukemia. J. Clin. Oncol. 2005;23:7161–7167. PubMed

Moghrabi A, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109:896–904. PubMed PMC

Silverman LB, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211–1218. PubMed

Kaspers GJL, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 1997;90:2723–2729. PubMed

Appel IM, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: Results from a single agent window study. Leukemia. 2008;22:1665–1679. PubMed

Pieters R, et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet. 1991;338:399–403. PubMed

Álvarez-Garcia V, Tawil Y, Wise HM, Leslie NR. Mechanisms of PTEN loss in cancer: It’s all about diversity. Semin. Cancer Biol. 2019;59:66–79. PubMed

Martelli AM, et al. The key roles of PTEN in T-cell acute lymphoblastic leukemia development, progression, and therapeutic response. Cancers (Basel) 2019;11:629. PubMed PMC

Fruman DA, et al. The PI3K pathway in human disease. Cell. 2017;170:605–635. PubMed PMC

Pulido R. PTEN: A yin-yang master regulator protein in health and disease. Methods. 2015;77:3–10. PubMed

Manning BD, Cantley LC. AKT/PKB signaling: Navigating downstream. Cell. 2007;129:1261–1274. PubMed PMC

Hermanova I, et al. Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells. Leukemia. 2016;30:209–218. PubMed

Hlozkova K, et al. Metabolic profile of leukemia cells influences treatment efficacy of l-asparaginase. BMC Cancer. 2020;20:526. PubMed PMC

Szarzyńska-Zawadzka B, et al. PTEN abnormalities predict poor outcome in children with T-cell acute lymphoblastic leukemia treated according to ALL IC-BFM protocols. Am. J. Hematol. 2019;94:E93–E96. PubMed

Jenkinson S, et al. Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial. Leukemia. 2016;30:39–47. PubMed PMC

Paganin M, et al. The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols. Br. J. Haematol. 2018;182:705–711. PubMed

Tesio M, et al. Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia. Leukemia. 2017;31:2594–2600. PubMed

Bandapalli OR, et al. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica. 2013;98:928–936. PubMed PMC

Evangelisti C, et al. Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review) Int. J. Oncol. 2014;45:909–918. PubMed

Hung YP, et al. Akt regulation of glycolysis mediates bioenergetic stability in epithelial cells. Elife. 2017;6:e27293. PubMed PMC

Elstrom RL, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64:3892–3899. PubMed

Zuurbier L, et al. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. Haematologica. 2012;97:1405–1413. PubMed PMC

Mendes RD, Canté-Barrett K, Pieters R, Meijerink JPP. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia. Haematologica. 2016;101:1010–1017. PubMed PMC

O’Neil J, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors. J. Exp. Med. 2007;204:1813–1824. PubMed PMC

Arruga F, et al. Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22. Leukemia. 2017;31:1882–1893. PubMed

Wang S, et al. Diminished interaction between mutant NOTCH1 and the NuRD corepressor complex upregulates CCL17 in chronic lymphocytic leukemia. Leukemia. 2019;33:2951–2956. PubMed

Xu Z, Stokoe D, Kane LP, Weiss A. The inducible expression of the tumor suppressor gene PTEN promotes apoptosis and decreases cell size by inhibiting the PI3K/Akt pathway in Jurkat T cells. Cell Growth Differ. 2002;13:285–296. PubMed

Yallop CA, Svendsen I. The effects of G418 on the growth and metabolism of recombinant mammalian cell lines. Cytotechnology. 2001;35:101–114. PubMed PMC

Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal J. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets. 2008;8:187–198. PubMed

Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646–674. PubMed

Teicher BA, Linehan WM, Helman LJ. Targeting cancer metabolism. Clin. Cancer Res. 2012;18:5537–5545. PubMed PMC

Guo K, Tang W, Zhuo H, Zhao G. Recent advance of Akt inhibitors in clinical trials. ChemistrySelect. 2019;4:9040–9044.

Lebok P, et al. Partial PTEN deletion is linked to poor prognosis in breast cancer. BMC Cancer. 2015;15:1–10. PubMed PMC

Mccall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J. Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br. J. Cancer. 2008;99:1296–1301. PubMed PMC

Cheung LWT, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011;1:170–185. PubMed PMC

Welm BE, Dijkgraaf GJP, Bledau AS, Welm AL, Werb Z. Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer. Cell Stem Cell. 2008;2:90–102. PubMed PMC

Hermanova I, Zaliova M, Trka J, Starkova J. Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to l-asparaginase. Exp. Hematol. 2012;40:657–665. PubMed

Chevrier S, et al. Compensation of signal spillover in suspension and imaging mass cytometry. Cell Syst. 2018;6:612–620.e5. PubMed PMC

Saeed AI, et al. TM4: A free, open-source system for microarray data management and analysis. Biotechniques. 2003;34:374–378. PubMed